The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Multiple Myeloma Therapeutics Market Research Report 2025
Synopsis
Multiple Myeloma (MM) is a haematological malignancy considered by the propagation of plasma cells in the bone marrow. The disease is incurable; though over the few years there have been substantial developments in therapy, determined by a greater understanding of pathophysiology. Multiple myeloma is common among men as compared to women and also arises commonly with growing age.
The global Multiple Myeloma Therapeutics market was valued at US$ 27270 million in 2023 and is anticipated to reach US$ 55870 million by 2030, witnessing a CAGR of 10.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Multiple Myeloma Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Myeloma Therapeutics.
Report Scope
The Multiple Myeloma Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Myeloma Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Myeloma Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Janssen Biotech, Inc.
Bristol-Myers Squibb
Novartis AG
Bristol-Myers Squibb Company
Millennium Pharmaceuticals
Celgene Corporation
Kesios Therapeutics Limited
Amgene, Inc.
Genzyme Corporation
Juno Therapeutics
Segment by Type
Chemotherapy
Radiation
Stem Cell Transplant
Other Supportive Treatments
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Multiple Myeloma Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Multiple Myeloma (MM) is a haematological malignancy considered by the propagation of plasma cells in the bone marrow. The disease is incurable; though over the few years there have been substantial developments in therapy, determined by a greater understanding of pathophysiology. Multiple myeloma is common among men as compared to women and also arises commonly with growing age.
The global Multiple Myeloma Therapeutics market was valued at US$ 27270 million in 2023 and is anticipated to reach US$ 55870 million by 2030, witnessing a CAGR of 10.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Multiple Myeloma Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Myeloma Therapeutics.
Report Scope
The Multiple Myeloma Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Myeloma Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Myeloma Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Janssen Biotech, Inc.
Bristol-Myers Squibb
Novartis AG
Bristol-Myers Squibb Company
Millennium Pharmaceuticals
Celgene Corporation
Kesios Therapeutics Limited
Amgene, Inc.
Genzyme Corporation
Juno Therapeutics
Segment by Type
Chemotherapy
Radiation
Stem Cell Transplant
Other Supportive Treatments
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Multiple Myeloma Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Multiple Myeloma Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chemotherapy
1.2.3 Radiation
1.2.4 Stem Cell Transplant
1.2.5 Other Supportive Treatments
1.3 Market by Application
1.3.1 Global Multiple Myeloma Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Multiple Myeloma Therapeutics Market Perspective (2019-2030)
2.2 Multiple Myeloma Therapeutics Growth Trends by Region
2.2.1 Global Multiple Myeloma Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Multiple Myeloma Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Multiple Myeloma Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Multiple Myeloma Therapeutics Market Dynamics
2.3.1 Multiple Myeloma Therapeutics Industry Trends
2.3.2 Multiple Myeloma Therapeutics Market Drivers
2.3.3 Multiple Myeloma Therapeutics Market Challenges
2.3.4 Multiple Myeloma Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Multiple Myeloma Therapeutics Players by Revenue
3.1.1 Global Top Multiple Myeloma Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Multiple Myeloma Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Multiple Myeloma Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Multiple Myeloma Therapeutics Revenue
3.4 Global Multiple Myeloma Therapeutics Market Concentration Ratio
3.4.1 Global Multiple Myeloma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Multiple Myeloma Therapeutics Revenue in 2023
3.5 Multiple Myeloma Therapeutics Key Players Head office and Area Served
3.6 Key Players Multiple Myeloma Therapeutics Product Solution and Service
3.7 Date of Enter into Multiple Myeloma Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Multiple Myeloma Therapeutics Breakdown Data by Type
4.1 Global Multiple Myeloma Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Multiple Myeloma Therapeutics Forecasted Market Size by Type (2025-2030)
5 Multiple Myeloma Therapeutics Breakdown Data by Application
5.1 Global Multiple Myeloma Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Multiple Myeloma Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Multiple Myeloma Therapeutics Market Size (2019-2030)
6.2 North America Multiple Myeloma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Multiple Myeloma Therapeutics Market Size by Country (2019-2024)
6.4 North America Multiple Myeloma Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Multiple Myeloma Therapeutics Market Size (2019-2030)
7.2 Europe Multiple Myeloma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Multiple Myeloma Therapeutics Market Size by Country (2019-2024)
7.4 Europe Multiple Myeloma Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Multiple Myeloma Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Multiple Myeloma Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Multiple Myeloma Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Multiple Myeloma Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Multiple Myeloma Therapeutics Market Size (2019-2030)
9.2 Latin America Multiple Myeloma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Multiple Myeloma Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Multiple Myeloma Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Multiple Myeloma Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Multiple Myeloma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Multiple Myeloma Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Multiple Myeloma Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Janssen Biotech, Inc.
11.1.1 Janssen Biotech, Inc. Company Detail
11.1.2 Janssen Biotech, Inc. Business Overview
11.1.3 Janssen Biotech, Inc. Multiple Myeloma Therapeutics Introduction
11.1.4 Janssen Biotech, Inc. Revenue in Multiple Myeloma Therapeutics Business (2019-2024)
11.1.5 Janssen Biotech, Inc. Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Detail
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Multiple Myeloma Therapeutics Introduction
11.2.4 Bristol-Myers Squibb Revenue in Multiple Myeloma Therapeutics Business (2019-2024)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Multiple Myeloma Therapeutics Introduction
11.3.4 Novartis AG Revenue in Multiple Myeloma Therapeutics Business (2019-2024)
11.3.5 Novartis AG Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Detail
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Multiple Myeloma Therapeutics Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Multiple Myeloma Therapeutics Business (2019-2024)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 Millennium Pharmaceuticals
11.5.1 Millennium Pharmaceuticals Company Detail
11.5.2 Millennium Pharmaceuticals Business Overview
11.5.3 Millennium Pharmaceuticals Multiple Myeloma Therapeutics Introduction
11.5.4 Millennium Pharmaceuticals Revenue in Multiple Myeloma Therapeutics Business (2019-2024)
11.5.5 Millennium Pharmaceuticals Recent Development
11.6 Celgene Corporation
11.6.1 Celgene Corporation Company Detail
11.6.2 Celgene Corporation Business Overview
11.6.3 Celgene Corporation Multiple Myeloma Therapeutics Introduction
11.6.4 Celgene Corporation Revenue in Multiple Myeloma Therapeutics Business (2019-2024)
11.6.5 Celgene Corporation Recent Development
11.7 Kesios Therapeutics Limited
11.7.1 Kesios Therapeutics Limited Company Detail
11.7.2 Kesios Therapeutics Limited Business Overview
11.7.3 Kesios Therapeutics Limited Multiple Myeloma Therapeutics Introduction
11.7.4 Kesios Therapeutics Limited Revenue in Multiple Myeloma Therapeutics Business (2019-2024)
11.7.5 Kesios Therapeutics Limited Recent Development
11.8 Amgene, Inc.
11.8.1 Amgene, Inc. Company Detail
11.8.2 Amgene, Inc. Business Overview
11.8.3 Amgene, Inc. Multiple Myeloma Therapeutics Introduction
11.8.4 Amgene, Inc. Revenue in Multiple Myeloma Therapeutics Business (2019-2024)
11.8.5 Amgene, Inc. Recent Development
11.9 Genzyme Corporation
11.9.1 Genzyme Corporation Company Detail
11.9.2 Genzyme Corporation Business Overview
11.9.3 Genzyme Corporation Multiple Myeloma Therapeutics Introduction
11.9.4 Genzyme Corporation Revenue in Multiple Myeloma Therapeutics Business (2019-2024)
11.9.5 Genzyme Corporation Recent Development
11.10 Juno Therapeutics
11.10.1 Juno Therapeutics Company Detail
11.10.2 Juno Therapeutics Business Overview
11.10.3 Juno Therapeutics Multiple Myeloma Therapeutics Introduction
11.10.4 Juno Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2019-2024)
11.10.5 Juno Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
